This HTML5 document contains 60 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n16http://linked.opendata.cz/ontology/domain/vavai/riv/typAkce/
dctermshttp://purl.org/dc/terms/
n20http://purl.org/net/nknouf/ns/bibtex#
n6http://localhost/temp/predkladatel/
n9http://linked.opendata.cz/resource/domain/vavai/projekt/
n8http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n19http://linked.opendata.cz/ontology/domain/vavai/
n5http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F61989592%3A15110%2F10%3A10215602%21RIV11-MZ0-15110___/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n14http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F61989592%3A15110%2F10%3A10215602%21RIV11-MZ0-15110___
rdf:type
skos:Concept n19:Vysledek
dcterms:description
In order to analyze the impact of IPL measurement on treatment results we have introduced the determination of IPL into our laboratory follow-up of CML patients in 2007. IPL were measured by UHPLC-TMS. 553 samples from 112 patients with CML treated at least 18 months and between 24?6 hours after the ingestion were used for statistics. We did not found correlation between IPL and probability of achievement of optimal cytogenetic or molecular response. We found high IPL inter-individual (394-3133 mg/l) and intra-individual variability (14.2-43.3%). In two patients with low IPL dose escalation led to IPL increase and improvement of treatment response. We were not able to demonstrate a clear correlation between IPL and response to imatinib therapy in our group of patients with CML. On the other hand in selected patients with low IPL and suboptimal response we were able to demonstrate that escalation of imatinib dose lead to optimal treatment response. In order to analyze the impact of IPL measurement on treatment results we have introduced the determination of IPL into our laboratory follow-up of CML patients in 2007. IPL were measured by UHPLC-TMS. 553 samples from 112 patients with CML treated at least 18 months and between 24?6 hours after the ingestion were used for statistics. We did not found correlation between IPL and probability of achievement of optimal cytogenetic or molecular response. We found high IPL inter-individual (394-3133 mg/l) and intra-individual variability (14.2-43.3%). In two patients with low IPL dose escalation led to IPL increase and improvement of treatment response. We were not able to demonstrate a clear correlation between IPL and response to imatinib therapy in our group of patients with CML. On the other hand in selected patients with low IPL and suboptimal response we were able to demonstrate that escalation of imatinib dose lead to optimal treatment response.
dcterms:title
Measurement of trough imatinib plasma levels in patients with CML does not significantly correlate with treatment response but may be succesfully used in selected patients for dosage adjustment. Measurement of trough imatinib plasma levels in patients with CML does not significantly correlate with treatment response but may be succesfully used in selected patients for dosage adjustment.
skos:prefLabel
Measurement of trough imatinib plasma levels in patients with CML does not significantly correlate with treatment response but may be succesfully used in selected patients for dosage adjustment. Measurement of trough imatinib plasma levels in patients with CML does not significantly correlate with treatment response but may be succesfully used in selected patients for dosage adjustment.
skos:notation
RIV/61989592:15110/10:10215602!RIV11-MZ0-15110___
n3:aktivita
n18:P
n3:aktivity
P(NS9627), P(NS9949)
n3:dodaniDat
n14:2011
n3:domaciTvurceVysledku
n8:2714035 n8:6401309 n8:2249421 n8:8478325 n8:2556049 n8:9589864 n8:3461904 n8:9959459 n8:9788662 n8:8227659
n3:druhVysledku
n7:D
n3:duvernostUdaju
n11:S
n3:entitaPredkladatele
n5:predkladatel
n3:idSjednocenehoVysledku
270063
n3:idVysledku
RIV/61989592:15110/10:10215602
n3:jazykVysledku
n4:eng
n3:klicovaSlova
UHPLC-TMS; correlation; treatment response; imatinib plasma levels
n3:klicoveSlovo
n10:treatment%20response n10:imatinib%20plasma%20levels n10:UHPLC-TMS n10:correlation
n3:kontrolniKodProRIV
[BB5E5DD02710]
n3:mistoKonaniAkce
Barcelona, Spain
n3:mistoVydani
Pavia
n3:nazevZdroje
Haematologica: the hematology journal
n3:obor
n13:FD
n3:pocetDomacichTvurcuVysledku
10
n3:pocetTvurcuVysledku
10
n3:projekt
n9:NS9627 n9:NS9949
n3:rokUplatneniVysledku
n14:2010
n3:tvurceVysledku
SKOUMALOVÁ, Ivana ADAM, Tomáš Divoká, Martina Faber, Edgar Rožmanová, Šárka FRIEDECKÝ, David Indrák, Karel Jarošová, Marie ROHOŇ, Peter MIČOVÁ, Kateřina
n3:typAkce
n16:EUR
n3:wos
000279051301143
n3:zahajeniAkce
2010-06-10+02:00
s:issn
0390-6078
s:numberOfPages
2
n20:hasPublisher
Fondazione Ferrata Storti
n6:organizacniJednotka
15110